in this issue
EnviroTech :: Biotech
Boehringer Ingelheim Launches Venture Capital Fund
5:12 AM MDT | March 31, 2010 | Deepti Ramesh
Boehringer Ingelheim (Ingelheim, Germany) says it has launched a corporate venture capital fund, Boehringer Ingelheim Venture Fund (BIVF), which aims to invest in biotechnology and start-up companies that provide groundbreaking therapeutic approaches and technologies to help drive innovation in medical science. These will include new therapeutic concepts including stem cells and RNA silencing, as well as new-generation vaccines, new-generation protein or antibody technologies, new molecular targets, and/or first-in-class lead compounds, as well as disease-related...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee